These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 10561340)
1. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. Brewer M; Gershenson DM; Herzog CE; Mitchell MF; Silva EG; Wharton JT J Clin Oncol; 1999 Sep; 17(9):2670-75. PubMed ID: 10561340 [TBL] [Abstract][Full Text] [Related]
2. Pregnancy outcomes and menstrual function after fertility sparing surgery for pure ovarian dysgerminomas. Boran N; Tulunay G; Caliskan E; Köse MF; Haberal A Arch Gynecol Obstet; 2005 Feb; 271(2):104-8. PubMed ID: 15007601 [TBL] [Abstract][Full Text] [Related]
3. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Kang H; Kim TJ; Kim WY; Choi CH; Lee JW; Kim BG; Bae DS Gynecol Oncol; 2008 Oct; 111(1):106-10. PubMed ID: 18656249 [TBL] [Abstract][Full Text] [Related]
4. Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour. Satoh T; Aoki Y; Kasamatsu T; Ochiai K; Takano M; Watanabe Y; Kikkawa F; Takeshima N; Hatae M; Yokota H; Saito T; Yaegashi N; Kobayashi H; Baba T; Kodama S; Saito T; Sakuragi N; Sumi T; Kamura T; Yoshikawa H Eur J Cancer; 2015 Feb; 51(3):340-51. PubMed ID: 25559616 [TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic complete remission in patients with metastatic ovarian dysgerminoma. Potential for cure and preservation of reproductive capacity. Gershenson DM; Wharton JT; Kline RC; Larson DM; Kavanagh JJ; Rutledge FN Cancer; 1986 Dec; 58(12):2594-9. PubMed ID: 2430686 [TBL] [Abstract][Full Text] [Related]
6. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. Gershenson DM; Morris M; Cangir A; Kavanagh JJ; Stringer CA; Edwards CL; Silva EG; Wharton JT J Clin Oncol; 1990 Apr; 8(4):715-20. PubMed ID: 1690272 [TBL] [Abstract][Full Text] [Related]
7. Late recurrence in ovarian dysgerminoma with successful response to standard adjuvant chemotherapy: a case report and review of the literature. Jeyakumar A; Cabeza R; Hindenburg A Gynecol Oncol; 2001 May; 81(2):314-7. PubMed ID: 11330968 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group. Williams SD; Blessing JA; Hatch KD; Homesley HD J Clin Oncol; 1991 Nov; 9(11):1950-5. PubMed ID: 1719142 [TBL] [Abstract][Full Text] [Related]
9. [A case of PEP(BEP)-resistant ovarian dysgerminoma successfully treated by VeIP therapy]. Ishibashi M; Nakayama K; Oride A; Yeasmin S; Katagiri A; Iida K; Nakayama N; Miyazaki K Gan To Kagaku Ryoho; 2009 Mar; 36(3):513-7. PubMed ID: 19295284 [TBL] [Abstract][Full Text] [Related]
10. Pure Immature Teratoma of the Ovary in Adults: Thirty-Year Experience of a Single Tertiary Care Center. Alwazzan AB; Popowich S; Dean E; Robinson C; Lotocki R; Altman AD Int J Gynecol Cancer; 2015 Nov; 25(9):1616-22. PubMed ID: 26332392 [TBL] [Abstract][Full Text] [Related]
11. Ovarian sertoli-leydig cell tumors: A multicenter long-term clinicopathological analysis of 27 patients. Akman L; Ertas IE; Gokcu M; Terek MC; Sanci M; Sanli UA; Zekioglu O; Ozsaran AA J Cancer Res Ther; 2016; 12(1):290-4. PubMed ID: 27072253 [TBL] [Abstract][Full Text] [Related]
12. Ovarian dysgerminoma with massive metastases to para-aortic lymph nodes. Takemori M; Ichimura T; Nishimura R; Hasegawa K Gynecol Obstet Invest; 2000; 49(3):211-3. PubMed ID: 10729765 [TBL] [Abstract][Full Text] [Related]
13. Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. de La Motte Rouge T; Pautier P; Duvillard P; Rey A; Morice P; Haie-Meder C; Kerbrat P; Culine S; Troalen F; Lhommé C Ann Oncol; 2008 Aug; 19(8):1435-1441. PubMed ID: 18408223 [TBL] [Abstract][Full Text] [Related]
14. Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors. Cicin I; Saip P; Guney N; Eralp Y; Ayan I; Kebudi R; Topuz E Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):210-4. PubMed ID: 19419810 [TBL] [Abstract][Full Text] [Related]
15. Paediatric dysgerminoma: Results of three consecutive French germ cell tumours clinical studies (TGM-85/90/95) with late effects study. Duhil de Bénazé G; Pacquement H; Faure-Conter C; Patte C; Orbach D; Corradini N; Berger C; Sudour-Bonnange H; Vérité C; Martelli H; Fresneau B Eur J Cancer; 2018 Mar; 91():30-37. PubMed ID: 29331749 [TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients. Li J; Yang W; Wu X Gynecol Oncol; 2007 Jun; 105(3):769-75. PubMed ID: 17459461 [TBL] [Abstract][Full Text] [Related]
17. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. Dimopoulos MA; Papadopoulou M; Andreopoulou E; Papadimitriou C; Pavlidis N; Aravantinos G; Aspropotamitis A; Anagnostopoulos A; Fountzilas G; Michalas S; Pectacides D Gynecol Oncol; 1998 Jul; 70(1):70-4. PubMed ID: 9698477 [TBL] [Abstract][Full Text] [Related]
18. Treatment of malignant ovarian germ cell tumors with preservation of fertility: reproductive performance after persistent remission. Kanazawa K; Suzuki T; Sakumoto K Am J Clin Oncol; 2000 Jun; 23(3):244-8. PubMed ID: 10857886 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Williams SD; Kauderer J; Burnett AF; Lentz SS; Aghajanian C; Armstrong DK Gynecol Oncol; 2004 Dec; 95(3):496-9. PubMed ID: 15581952 [TBL] [Abstract][Full Text] [Related]
20. Conservative surgical management of malignant ovarian germ cell tumors: the experience of the Gynecologic Oncology Unit at Ain Shams University. El-Lamie IK; Shehata NA; Abou-Loz SK; El-Lamie KI Eur J Gynaecol Oncol; 2000; 21(6):605-9. PubMed ID: 11214621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]